Jounce Therapeutics Inc (JNCE) Receives $14.80 Average PT from Analysts

Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have received an average rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $14.80.

A number of research analysts have recently commented on the company. Cowen cut Jounce Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 5th. Raymond James began coverage on Jounce Therapeutics in a research note on Thursday, June 28th. They set an “outperform” rating and a $13.00 price objective for the company. HC Wainwright set a $33.00 price objective on Jounce Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. Wells Fargo & Co cut Jounce Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $37.00 to $13.00 in a research note on Thursday, May 17th. Finally, Zacks Investment Research cut Jounce Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 12th.

Large investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC purchased a new position in shares of Jounce Therapeutics in the first quarter worth $159,000. Rhumbline Advisers purchased a new position in shares of Jounce Therapeutics in the fourth quarter worth $134,000. Cubist Systematic Strategies LLC purchased a new position in shares of Jounce Therapeutics in the first quarter worth $243,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Jounce Therapeutics in the first quarter worth $313,000. Finally, Teachers Advisors LLC raised its stake in shares of Jounce Therapeutics by 59.3% in the fourth quarter. Teachers Advisors LLC now owns 25,542 shares of the company’s stock worth $326,000 after purchasing an additional 9,507 shares during the last quarter. Institutional investors and hedge funds own 91.98% of the company’s stock.

Shares of Jounce Therapeutics traded up $0.31, reaching $7.23, on Tuesday, according to Marketbeat Ratings. The stock had a trading volume of 324,164 shares, compared to its average volume of 271,074. Jounce Therapeutics has a 12-month low of $6.56 and a 12-month high of $29.25.

Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Wednesday, May 9th. The company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.09). The firm had revenue of $11.20 million during the quarter, compared to analysts’ expectations of $13.33 million. Jounce Therapeutics had a negative net margin of 47.73% and a negative return on equity of 19.90%. research analysts expect that Jounce Therapeutics will post -1.56 earnings per share for the current fiscal year.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Featured Article: Understanding Stock Ratings

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply